• SENSEX
    NIFTY 50
Healthcare

Why Glenmark Pharmaceuticals is on a deal spree

Updated : August 17, 2018 01:53 PM IST

Glenmark on July 6th announced an exclusive licensing agreement with Australian company Seqirus for one of its drug under development Ryaltris or GSP 301.
A month later after the Ryaltris deal, Glenmark announced an exclusive licensing agreement for its oncology molecule under development- GBR 1302.
The third deal announced by Glenmark was with its Q1FY19 numbers on 10th of August, just a few days after the agreement on Ryaltris.
Why Glenmark Pharmaceuticals is on a deal spree
primo org
Have you signed up for Primo, our daily newsletter?
It has all the stories and data on the market, business, economy and tech that you need to know.
cnbc two logos
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more

You May Also Like

Live TV